Life science research tools market size, growth and trends (2013-2021) - Table of Contents - DeciBio
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Life science research tools
market size, growth and trends
(2013-2021) – Table of Contents
July, 2017
4th edition
Information contained in this market report is believed to be reliable
at the time of publication. DeciBio is not soliciting any action based
on the information contained in this report. See appendix section for
complete disclosures.
DeciBio, LLC
Email: info@decibio.com
www.decibio.com
1Agenda
• Introduction
• Executive Summary
• Pure Genomics Tools
• Pure Proteomics Tools
• Cell Biology Tools
• Other Analytical Technologies
• Other Supplies and Technologies
• Appendix
2DeciBio forecasts that the LS research tools market will grow at ~5% p.a. in
the next 4 years, driven by biopharma and applied (e.g., food testing) markets
Online Abstract
The fourth edition of this report provides an overview of the life sciences research tools market from 2013 to 2021. Life sciences research tools
companies offer instruments, reagents and services to academic, BioPharma, applied market and (non-IVD) clinical customers. This market is
consolidated, with top vendors including Agilent, Bio-Rad, Illumina, Life Technologies*, MilliporeSigma, and Thermo Fisher representing the
majority of sales; however, mid-size players (e.g., Luminex, NanoString) and smaller emerging players are highlighted and included in this
report as well (e.g., Oxford Nanopore, Quanterix, Seahorse Biosciences***).
As in previous versions, we carefully triangulated market growth with past and forecasted organic growth from keys players, many of which
have experienced growth driven by acquisition. As a result, segmenting the market by technology, we estimate that the life science research
tools market will reach $52.5B in 2017, and is expected to grow ~5% p.a. in the next 4 years. These figures are in contrast with other reports
on individual technologies that report bullish growth rates of 5%-20% for many technologies. Our analysis confirms that within academia,
growth will continue to be strong in emerging markets (e.g., China, India) offset by weakness in academic funding in developed countries (e.g.,
Japan, Europe). With that said, our analysis confirms that applied markets (such as non-IVD clinical / LDT’s, forensics or AgBio customers)
might experience double digit growth for many technologies. This report evaluates which technologies are expected to capture (e.g., NGS,
mass spectrometry) and lose (e.g., PCR) relative market share.
In this fourth edition, we updated our analysis to reflect the most current market sales and trends in five broad segments:
1) Pure genomics technologies: PCR, qPCR, next generation sequencing (NGS) / third generation sequencing (3GS), CE sequencing, microarrays,
molecular biology tools, digital PCR;
2) Pure proteomics technologies: Antibodies, ELISA, protein production, western blots and protein microarrays^;
3) Cell biology technologies: discovery services, microscopy, basic cell biology reagents, flow cytometry, transfection and electroporation, media and
sera, cell culture equipment, cells and tissues, whole cell analysis, high content imaging;
4) Other analytical technologies: liquid chromatography, mass spectroscopy, structural analysis methods, in vivo study, spectroscopy, multiplex
technologies, label free technologies;
5) Other supplies and technologies: lab supplies and disposables, automation, glassware, sample preparation, LIMS, magnetic beads
For each of these 35 subsegments, we present an analysis detailing sales of instruments and reagents for 2013, 2017 and 2021. In addition,
we detail market drivers (e.g., increased government funding in emerging markets) and moderators (e.g., pricing pressure for some
technologies), market trends (e.g., shift of pharma interest from small molecule to large molecule drugs, interest in single cell analysis), a high
level end-customer breakdown (Academic, BioPharma and Applied markets customers) and key competitors.
All data are based on manufacturer sales as publicly reported, and a total of 37 interviews^^ with life sciences experts in academic, BioPharma
and applied market laboratories conducted.
Note: * Now part of Thermo Fisher; ** Now part of MilliporeSigma; *** Now part of Agilent; ^ Including next-generation multiplex proteomics platforms (e.g.,
Quanterix); ^^Majority of the interviews were done prior to the 4th edition 3This report is divided in the following sections
Table of Contents
Introduction 2 Pure proteomics tools 31 Other Analytical Tech. (continued)
Abstract 3 LS proteomics market by technology 32 In vivo study 57
Table of contents 4 Antibody 33 Spectroscopy 58
4th edition: what’s new? 5 Protein production 34 Multiplex technologies 59
Included / excluded technologies 6 Label free technologies 60
ELISA 35
Definition (product types) 7 Emerging technologies in Other Anal. Tech. 61
Western blots 36
Definition (end-customer types) 8
Protein microarrays 37 Other Supplies and Technologies 62
Methodology 9
Emerging technologies in Proteomics 38 Other supplies & tech. market by technology 63
Technology timeline 10
Cell Biology Tools 39 Lab supplies and disposables 64
Executive Summary 11
Laboratory Automation 65
LS cell biology market by technology 40
LS market by category 12
Glassware 66
LS market by geography Cell Based Assay Discovery services 41
13
Sample preparation 67
LS market by customer type 14 Optical and fluorescence microscopy 42
LIMS 68
LS market by product type 15 Basic cell biology reagent 43
Magnetic beads 69
NIH funding trends 16 Flow cytometry 44
Emerging technologies in Other supplies & tech. 70
LS players strategic moves 17 Transfection and electroporation 45
Highlights on China strategy, 5-Year Plan 18 Appendix 71
Media and sera 46
Interests in single cell analysis 20 Highlights on CRISPR 72
Cell culture equipment and plasticware 47
Pure Genomics Tools 21 Positioning of key players 75
Cells and tissues 48
Revenue guidance from key players 76
LS genomics market by technology 22 Whole cell analysis 49
NIH funding analysis 77
qPCR 23 High content imaging 50
NGS 24 In vitro diagnostics (IVD) market 78
Emerging technologies in Cell Biology 51
Microarrays 25 Molecular diagnostics (MDx) market 79
Other Analytical Technologies 52 CE instrument decommission 80
PCR 26
LS analytical tools by technology 53 Abbreviations 81
CE sequencing 27
Molecular biology 28 Liquid chromatography 54 About DeciBio 82
Digital PCR 29 Mass spectroscopy 55 Related DeciBio reports 83
Emerging technologies in Genomics 30 Structural analysis 56 Disclosure 84
44th edition: What’s new?
Updated Content Updated Market Numbers*
• Incorporated the latest trends in the life science • Updated all market numbers for 2017 market size
research tools market based on secondary research and latest trends
• Updated market numbers in light of increased interest • Validated and refined our former projections of
in single cell analysis: growth rates for key technologies, such as:
o Single cell genomics o Lab Automation: Slightly accelerated market growth
o Single cell proteomics o Bioinformatics / LIMS: Slightly accelerated market growth
• Updated content on the China strategy of select key o NGS: Moderately accelerated market growth
industry players o Digital PCR: Moderately accelerated market growth
o Label-free market: Slightly decelerated market growth
• Expanded our analysis to include the impact of
China’s Five-Year Plan on the market • Adjusted market size and growth for some markets
o Media and sera: Reassessed market size given the shift of
• Incorporated our analysis on emerging technologies R&D spending from small molecule to biopharmaceuticals
in each technology segment
o High Content Imaging: Added ~$140M, the aggregate
revenues for players that have not been accounted for in
Updated Market Trends the 3rd edition
• Reassessed market trends for: o Digital PCR: Reassessed market size given recent product
introduction (e.g., ddPCR from Bio-Rad)
o Microarrays given renewed interest in this technology from
AgBio customers for production mode applications o Microarrays: Increased growth rate to reflect positive
uptake by biobanking, AgBio, and DTC markets
o NGS in light of recent product introduction (e.g., NovaSeq)
and precision medicine initiatives across the globe o Antibodies: Reassessed market size given the continued
R&D investment in companion diagnostics by the
o Liquid Chromatography / Mass spectrometry given pharmaceutical industry
adoption of LC-MS methods in the regulated testing and
development of large molecule drugs o Protein Microarrays / Western blot: Reassessed market
size based on a more rigorous modeling approach
Note: * Most significant changes only; additional adjustments have been made based on primary and secondary research data analysis 5This report assesses the WW market size, growth and trends of the life science
(LS) research tools space; it includes and excludes the following technologies
Technologies included Technologies excluded
• Pure genomic tools • Other analytical technologies and • In vitro diagnostics
o qPCR sample preparation* o Point-of care tests
o Next generation sequencing (NGS) / o Liquid chromatography o Clinical chemistry
Third generation sequencing (3GS) o Mass spectroscopy o Immunoassays / Radioimmunoassays
o Microarrays o Structural analysis o Hematology* / Coagulation assays
o PCR o in vivo study o Microbiology
o CE Sequencing o Spectroscopy o Molecular diagnostics
o Molecular biology** o Multiplex technologies
o Digital PCR o Label free technologies • Medical tools and safety
o Hospital equipment
• Pure proteomic tools • Lab supplies and disposables o Surgical tools / Safety devices
o Protein isolation and analysis o Basic supplies and disposables o Blood collection products
o Protein production o Liquid handling and automation
o ELISA o Glassware • Other life science technologies
o Western blots o Sample preparation o Synthetic biology (including nucleic acid
o Protein microarrays o Bioinformatics / LIMS synthesis)
o Magnetic beads o Electrophysiology and patch clamp
• Cell biology tools
o Discovery services
o Microscopy • Other niche markets***
o Basic cell biology reagents
o Flow cytometry • Combinatorial chemistry
o Transfection and electroporation
o Media and sera • Medical devices
o Cell culture equipment and
plasticware
o Cells and tissues
o Whole cell imaging
o High content imaging (HCI)
Note: * Some of these tools can be used to study both genomics and proteomics
** Molecular biology includes key products such as enzymes (e.g., restriction enzymes), vectors, viruses (e.g., lentivirus kits), cloning systems, cDNA libraries,
and various kits and reagents (see slide 28)
*** Small markets such as laser capture microscopy, digital barcoded arrays (i.e., Nanostring)
Source: DeciBio analysis 6Market sizes for each of the 35 technologies are reported as instrument or
reagent revenues
Product Types
• Instruments include systems and platforms used for sample preparation or analysis,
and that typically require an energy source (e.g., 110V / 220V, battery)*
Instruments o Example instruments include sequencers, mass spectrometers, PCR thermal cyclers or pH meters
(Instruments, Service
Contract and Software) • Many users purchase a service contract (or annual maintenance agreement) to “insure”
the instrument and guarantee timely repair when necessary
o Service contracts typically vary from 8-15% of instrument purchase price (per year)
• Software run complex instruments often required to be connected to a computer for
operation and data analysis
• Reagents and kits are products that are used (either in combination or independent of
an instrument) in order to analyze a sample
Reagents o Example reagents include PCR primers, antibodies, and cells
(Reagents, Consumables
and Services) • Consumables are products used in order to conduct the experiment, but that are not
necessarily directly involved in the analytical process
o Example consumables include pipette tips, gloves, and glassware
• Services are experiments conducted for a lab by a life science research tools
manufacturer (not another laboratory, core facility or CRO)
o Example services include sequencing services from Complete Genomics, bioproduction services
from Thermo Fisher, discovery services from MilliporeSigma
Note: * Exceptions exist (e.g., pipettes, some cell counters)
Source: DeciBio analysis 7Customers were separated in 3 groups: academic and government labs,
biopharma, and applied markets
Customer Types
Academia and Government BioPharma* Applied Markets
• For-profit organizations developing
• Non-profit customers and centers • For-profit or government-funded
therapies for treatment of diseases
relying on government funding, institutions and laboratories
such as cancer or Alzheimer’s
primarily from the NIH in the U.S.** • Testing (and some basic research
Definition • Preclinical research (and some use
• Basic and translational research [e.g., in AgBio])
during clinical trials)
• Incentive to innovate: High (very early • Incentive to innovate: Low to moderate
• Incentive to innovate: Moderate to high
technology adopter) (late technology adopter****)
(early technology adopter)
• Stanford Professor (Academia) • DuPont (AgBio)
• USCD Associate Professor • Pfizer (Large Pharma) • Vet. diagnostic labs (Animal health)
(Academia) • Novartis (Large Pharma) • Central science lab (Biosecurity)
Example
• Missouri U. Core Lab Director • Amgen (Large Biotech) • IEH labs (Food safety)
customers (Academia) • Actellion (Small / Specialty Pharma) • FBI lab services (Forensics)
• NIH Post-Doctoral Fellow • Covance (CRO) • Clinical (Non-IVD) customers (e.g.,
(Government) Hospitals, reference labs)
Market size / $21.5B (~41% of total) / $19.4B (~37% of total) / ~$11.5B (~22% of total) /
growth (2017) 2% (2017-21 CAGR) 4% (2017-21 CAGR) 12% (2017-21 CAGR)
+ Continued interest in increasing ease
+ New innovation cycle driving shift to of use, reproducibility, and throughput
+ Increased funding in China and U.S. large molecule drugs at a lower cost per test
- Increased use of 2nd hand instrument + Increased interest in personalized + Increased use for compliance with
Key trends vendors (e.g., eBay, BioSurplus) medicine regulations (especially outside the
driving and - Flat or decreasing funding in most + Increased reliance on contract U.S.)
developed countries (e.g., Japan, research organizations (CRO) for
moderating Canada)
+ Adoption of novel technologies (e.g.,
preclinical studies NGS, mass spectrometry) in clinical
growth - Uncertainties in the funding settings (e.g., hospitals, reference
- Continued pressure on R&D funding
environment in Europe due to labs)
political, social issues (e.g., Brexit) - Patent expirations, with increased
competition from generics - Dependence on government funding
in some markets
Note: * BioPharma includes instrument and reagent purchased by CRO (not price of services charged to Biopharma)
** Centre national de la recherche scientifique (CNRS) in France, National Health Service (NHS) in the U.K.
*** Example foundations: HHMI, Gates foundation, Keck / Kavli / Doris Duke foundation)
**** Applied market customers typically adopt technologies 2-5 years after academic customers
Source: DeciBio analysis 8We used a combination of primary and secondary research to compile data
presented in this report*
Data and analysis
Primary research Secondary research
• Interviews with 37 experts** • Company financial information
o 13 academic professors and post-doctoral fellows*** o 10-K / 10-Q and associated earnings call transcripts
from leading institutions worldwide (~50% in the U.S.) o Company presentations
o 7 lab directors and senior scientists in large Pharma o Press releases
o 5 lab directors and senior scientists in small to mid-
size biotech companies • Company technical information
o 5 lab directors and scientists in applied markets o Company website
o 7 life science business experts / professionals o Company publications and posters
o Company technical sheets
• Interview content structure
o Funding • Other sources
o Current activity o PubMed
o Key players and technologies o Peer-reviewed publications and scientific posters
o Trends o Government reports and databases (e.g., NIH reporter)
o Future activity o Healthcare conferences (e.g., JP Morgan, Cowen)
We built a bottom-up market model by technology; growth rates obtained from interviewee feedback and
secondary research guidance were triangulated with the reality reflecting the current funding environment^
Note: * The 4th edition primarily focuses on secondary research; ** Overall: 21 interviews in the U.S., 11 in Europe and 5 in the rest of the world;
*** 2 post-doctoral fellows; ^ All interviews started with discussion of the funding environment, and interviewees were asked to reassess future
technology usage based on their current funding (e.g., what would they stop doing to fund new large scale RNA-Seq projects)
Source: DeciBio analysis 9Agenda
• Introduction
• Executive Summary
• Pure Genomics Tools
• Pure Proteomics Tools
• Cell Biology Tools
• Other Analytical Technologies
• Other Supplies and Technologies
• Appendix
10Major abbreviations used in this report
3GS: Third generation sequencing miRNA: microRNAs
AgBio: Agricultural biotechnology MDx: Molecular diagnostics
ARRA: American Recovery and Reinvestment Act MHC: Major histocompatibility complex
ATCC: American Type Culture Collection MRSA: Methicillin-resistant Staphylococcus aureus
BRIC: Brazil, India, China NA: Nucleic acid
CE Sequencing: Capillary electrophoresis sequencing ncRNA: non-coding RNAs
CAGR: Compound annual growth rate NGS: Next generation sequencing
CGH: Comparative genomic hybridization NIH: National institute of Health
CNV: Copy number variation NMR: Nuclear magnetic resonance
COLD PCR: Co-amplification at lower denaturation OEM: Original equipment manufacturer
temperature-PCR p.a.: Per annum
CMO: Contract manufacturing organization PCR: Polymerase chain reaction
CRO: Contract research organization PGM: Personal genome machine
Dx: Diagnostics Pharma QA/QC: Pharma quality assurance and quality control
ELISA: Enzyme-linked immunosorbent assay POC: Point-of-care
GPCR: G protein-coupled receptors QA / QC: Quality assurance / quality control
HCI: High content imaging qPCR: quantitative PCR
HHMI: Howard Hughes Medical Institute R&D: Research and Development
HLA: Human leukocyte antigen RNA: Ribonucleic acid
HPLC: High-performance liquid chromatography ROW: Rest of world
HPV: Human papillomavirus RUO: Research use only
HTS: High throughput screening SNP: Single nucleotide polymorphism
IVD: in vitro diagnostic SPR: Surface plasmon resonance
KO: Knock-out TBD: To-be-determined
LGC: Large genome center UCSD: University of California San Diego
LIMS: Laboratory information management system UCSF: University of California San Francisco
LS: Life sciences UHTS: Ultra-high throughput screening
MALDI-TOF: Matrix-assisted laser desorption/ionization-time WW: Worldwide
of flight
11We developed this report assembling a team of experts in this space
• Who is DeciBio?
o DeciBio is the industry leader in market intelligence and advisory services for the diagnostics and life sciences research
tools industries. Our staff is comprised primarily of experienced experts with clinical, research, and industry experience.
Our reports are purchased by the majority of the industry’s leading companies, investors, and other stakeholders
“ … The 4th edition of the MDx report is the best I’ve read in this space. DeciBio consistently segments market in ways that make sense to
us and our clients … ”
- Former Sr. Manager, McKinsey & Co
• Stephane Budel, Ph.D. is the primary author of this report. He brings:
o A Ph.D. from Yale University in neuroscience where he was an early adopter of NGS
o Experience as the author of more than 10 market research reports
o Over 15 years of combined life sciences and market research experience
• DeciBio has unequaled technical insight and analysis
o DeciBio doesn’t just provide the story today; we give you our expert opinion on what the future has in store
• DeciBio provides expert opinions on where the market is headed and why
o DeciBio provides not just standard market sizing information but deep insight into the technical aspects of the current and
future NGS market in a context that is clear and readable, especially to non-technical readers.
“ … What I like about DeciBio is that they don’t just give me a data dump, they provide real insight and expertise on the market that is
understandable to a lay person in the world of finance … ”
- M&A Banker, Top 10 investment bank
12If interested in this report, consider the following DeciBio reports
• Find related DeciBio reports on our website: www.decibio.com:
o Next Generation Sequencing: Market Size, Segmentation, Growth and Trends by
Provider (http://www.decibio.com/NGS)
o Single Cell Genomics (SCG): Market Size, Segmentation, Growth, Competition and
Trends (http://www.decibio.com/SCG)
• Contact us at info@decibio.com in order to receive information on our
DeciBio Marketbook, which provides additional granularity on these markets
13Disclosures
Information contained in this market report is believed to be reliable at the time of
publication. However, DeciBio does not warrant its accuracy or completeness.
Opinions, estimates and other information constitute the judgment of DeciBio, and can
be subject to change without notice.
DeciBio is not soliciting any action based on the information contained in this report.
This report is provided for informational purposes only and should not be construed as
a call for action.
DeciBio and its collaborators may own equity and/or securities related to any company
cited in this report, and engage in transactions inconsistent with this report.
This report and any access to it are intended to the buyer only. This report is published
by DeciBio, LLC. All rights reserved. Reproduction or redistribution of this report in any
form is prohibited without the prior consent of DeciBio, LLC.
This report may contain digital controls and custom watermarks for tracking purposes.
Please inquire about site license pricing for your institution by contacting
admin@decibio.com before sharing this document.
14You can also read
